skip to main |
skip to sidebar
Blog Archive
-
▼
2007
(90)
-
▼
October
(27)
- Wyeth, Tygacil for the Treatment of Patients with ...
- Tomophase, First Cross-Sectional Images Of Human B...
- Poniard Pharmaceuticals, Orphan Medicinal Product...
- Pharmion , Phase 3 Study of Amrubicin in Small Cel...
- DEY, Clinical Trials for Perforomist™ Inhalation S...
- Altair Therapeutics Will Develop Antisense Drugs f...
- Telik, TELCYTA Clinical Development
- Abraxis Bioscience, Special Protocol Assessment fo...
- Critical Therapeutics, Phase III Trial of Zileuton...
- Cellestis, FDA Approval for Blood Test for Detecti...
- Threshold Pharmaceuticals would stop enrollment in...
- Oridion, New Smart Capnography System for Improved...
- Proteolix , Carfilzomib in Subjects with Relapsed ...
- Nektar Therapeutics, NKTR-102 (PEG-Irinotecan) in ...
- Broncus Technologies, Encouraging Results Reported...
- Exelixis, Phase II study of XL647 in Patients with...
- MediciNova Positive Phase IIa Clinical Study Resul...
- PTC Therapeutics, Phase 2 Results of PTC124 in Cys...
- Inspire, Phase 3 Cystic Fibrosis Trial
- MedImmune , Phase 2 Safety Data for Anti-RSV Antib...
- Gilead, Phase III Study of Aztreonam Lysine for In...
- Invacare , new Invacare® XPO2™ extremely portable ...
- development of NOV-002, Novelos' lead compound in ...
- Critical Therapeutics, Phase I Clinical Trial of t...
- Emphasys Medical, PMA Submission for Bronchial Val...
- Discovery Laboratories, Surfaxin Process Validatio...
- FASgen, Significant Milestone in Its Cancer Drug D...
Wyeth, Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
October 24, 2007 — Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s supplemental New Drug Application (sNDA) for its first-in-class antibiotic Tygacil® (tigecycline) for the treatment of patients with community-acquired pneumonia (CAP)...
Wyeth's Press Release -
